New drug combo tested to shrink rectal tumors before surgery
NCT ID NCT04104139
Summary
This early-stage study aims to find the safest dose of the chemotherapy drug TAS-102 when given alongside radiation therapy to patients with stage II or III rectal cancer. The goal is to shrink the tumor before the patient undergoes standard surgery and follow-up chemotherapy. Researchers are primarily looking at side effects to determine the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.